NCT01731574已完成1 期
An Open-label, Randomized, Three-period Crossover Trial in Healthy HIV-negative Women to Assess the Drug-drug Interaction Between Dapivirine Vaginal Ring-004 and Miconazole Nitrate
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Dapivirine Area under the concentration time curve (AUC)
研究概览
简要总结
This trial will investigate the potential drug-drug interaction between dapivirine vaginal Ring-004 and vaginally administered miconazole nitrate, and will evaluate the safety of co-administration of the dapivirine vaginal ring and miconazole nitrate in healthy, HIV-negative women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women between 18 and ≤ 40 years of age who can give written informed consent
- •Available for all visits and consent to follow all procedures scheduled for the trial
- •Healthy, based on medical history, vital signs, physical examination, urinalysis (dipstick and microscopy (if indicated)), laboratory evaluations for genital infections (bacterial vaginosis, gonorrhoea, chlamydia and trichomonas), and laboratory evaluations for haematology and chemistry
- •HIV-negative as determined by an HIV test at the time of enrolment
- •On a stable form of contraception, defined as:
- •A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR
- •Transdermal contraceptive patch for at least 3 months prior to enrolment, OR
- •Long-acting progestins for at least 6 months prior to enrolment, OR
- •An IUD inserted (with no vaginal or gynaecological complaints associated with its use) at least 3 months prior to enrolment, OR
- •Have undergone surgical sterilisation at least 3 months prior to enrolment, AND willing to use oral contraceptives if necessary to delay menstruation during the vaginal sampling period
- •Upon pelvic examination at the time of enrolment, the cervix and vagina appear normal as determined by the Investigator/Physician
- •Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed with any treatable STI, either clinically or by laboratory test at the time of screening, she must receive treatment at least 2 weeks prior to enrolment)
- •Willing to refrain from the use of topical medications, vaginal products or objects, including female condoms, tampons, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method), douches, lubricants, vibrators/dildos, and drying agents for 14 days prior to enrolment and for the duration of the trial.
- •Documentation of no abnormality on cervical cytology, including grossly bloody smear, within 90 days prior to screening
- •Willing to refrain from participation in any other research trial for the duration of this trial
- •Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures, e.g. by home visit or telephone, or via family or close neighbour contacts (confidentiality to be maintained)
- •Willing to agree to abstain from all the following for a total of 2 days (48 hours) prior to each trial visit:
- •Penile-vaginal intercourse
- •Oral contact with her genitalia
- •Hepatitis B and C negative at the time of enrolment.
排除标准
- •Currently pregnant or had their last pregnancy outcome within 3 months prior to screening
- •Currently breast-feeding
- •Currently or within two months of participation in any other clinical research trial involving investigational or marketed products prior to screening
- •Untreated symptomatic urogenital infections, e.g. urinary tract or other sexually transmitted infections, or other gynaecological conditions such as vaginal itching, pain, or discharge, within 2 weeks prior to enrolment
- •Have a Grade 2 or higher pelvic examination finding, according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies
- •History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence or urge incontinence
- •Current vulvar or vaginal symptoms/abnormalities that could influence the trial results
- •Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation
- •Symptomatic genital herpes simplex virus (HSV) infection or a history of genital herpetic infection
- •Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at baseline (screening) according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies
- •Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrolment
- •Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or silicone
- •Any serious acute, chronic or progressive disease (e.g. any known history of neoplasm, cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, AIDS, or blood dyscrasias), or signs of cardiac disease, renal failure, or severe malnutrition
- •Have undergone a hysterectomy
- •Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives.
研究组 & 干预措施
Dapivirine Ring + Miconazole
Active Comparator
Dapivirine Ring + miconazole
干预措施: dapivirine (Drug)
Dapivirine Ring + Miconazole
Active Comparator
Dapivirine Ring + miconazole
干预措施: miconazole (Drug)
Dapivirine Ring
Experimental
Dapivirine Ring
干预措施: dapivirine (Drug)
结局指标
主要结局
Dapivirine Area under the concentration time curve (AUC)
时间窗: 24 hr, 14 days, and 28 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)HIV- PreventionNCT02847286International Partnership for Microbicides, Inc.36
已完成
1 期
Expanded Use PK of Dapivirine Vaginal RingPharmacokineticsNCT01952561International Partnership for Microbicides, Inc.40
已完成
1 期
PK and Safety Study of Vaginal Rings Containing Dapivirine and LevonorgestrelHIV PreventionNCT02855346International Partnership for Microbicides, Inc.24
已完成
3 期
Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant PairsHIV InfectionsNCT04140266National Institute of Allergy and Infectious Diseases (NIAID)394
已完成
1 期
A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy VolunteersHealthy VolunteerNCT01514968Hoffmann-La Roche18